Publicaciones en colaboración con investigadores/as de University of Bordeaux (19)

2024

  1. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies

    The Lancet HIV, Vol. 11, Núm. 2, pp. e106-e116

2023

  1. Correction: The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer (Molecular Cancer, (2023), 22, 1, (86), 10.1186/s12943-023-01788-w)

    Molecular Cancer

  2. The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer

    Molecular Cancer, Vol. 22, Núm. 1

2021

  1. Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation

    Nature Genetics, Vol. 53, Núm. 9, pp. 1311-1321

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2019

  1. European Society of Surgical Oncology's strategy for clinical research: Paving the way for a culture of research in cancer surgery

    European Journal of Surgical Oncology, Vol. 45, Núm. 9, pp. 1515-1519

2015

  1. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

2014

  1. Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice

    EMBO Molecular Medicine, Vol. 6, Núm. 10, pp. 1246-1262

2010

  1. Flavonoids inhibit hypoxia-induced vascular endothelial growth factor expression by a HIF-1 independent mechanism

    Biochemical Pharmacology, Vol. 79, Núm. 11, pp. 1600-1609

2001

  1. Correction of deficient CD34+ cells from peripheral blood after mobilization in a patient with congenital erythropoietic porphyria

    Molecular Therapy, Vol. 3, Núm. 3, pp. 411-417

  2. Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection

    Molecular Therapy, Vol. 4, Núm. 4, pp. 331-338

  3. Hepatic porphyrin concentration and uroporphyrinogen decarboxylase activity in hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 8, Núm. 1, pp. 41-47

  4. Successful therapeutic effect in a mouse model of erythropoietic protoporphyria by partial genetic correction and fluorescence-based selection of hematopoietic cells

    Gene Therapy, Vol. 8, Núm. 8, pp. 618-626

2000

  1. Reversion of hepatobiliary alterations by bone marrow transplantation in a murine model of erythropoietic protoporphyria

    Hepatology, Vol. 32, Núm. 1, pp. 73-81

1999

  1. A novel immunodeficient mouse model - RAG2 x common cytokine receptor γ chain double mutants - Requiring exogenous cytokine administration for human hematopoietic stem cell engraftment

    Journal of Interferon and Cytokine Research, Vol. 19, Núm. 5, pp. 533-541

  2. Fluorescence-based Selection of Retrovirally Transduced Cells in Congenital Erythropoietic Porphyria: Direct Selection Based on the Expression of the Therapeutic Gene

    Journal of Gene Medicine, Vol. 1, Núm. 5, pp. 322-330

  3. Perspectives de therapie genique en hematologie

    Annales de Biologie Clinique, Vol. 57, Núm. 1, pp. 43-50

1998

  1. Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: The influence of virus C infection

    Hepatology, Vol. 27, Núm. 2, pp. 584-589

1997

  1. Selection of down-regulated sequences along the monocytic differentiation of leukemic HL60 cells

    FEBS Letters, Vol. 414, Núm. 1, pp. 146-152